WO1997044469A3 - Multiple epitope fusion protein - Google Patents

Multiple epitope fusion protein Download PDF

Info

Publication number
WO1997044469A3
WO1997044469A3 PCT/US1997/008950 US9708950W WO9744469A3 WO 1997044469 A3 WO1997044469 A3 WO 1997044469A3 US 9708950 W US9708950 W US 9708950W WO 9744469 A3 WO9744469 A3 WO 9744469A3
Authority
WO
WIPO (PCT)
Prior art keywords
epitopes
epitope
amino acid
acid sequence
sequences
Prior art date
Application number
PCT/US1997/008950
Other languages
French (fr)
Other versions
WO1997044469A2 (en
WO1997044469A8 (en
Inventor
Pablo D T Valenzuela
David Ying Chien
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/653,226 external-priority patent/US6514731B1/en
Priority to NZ333431A priority Critical patent/NZ333431A/en
Priority to DE69734776T priority patent/DE69734776T2/en
Priority to EP97927767A priority patent/EP0935662B1/en
Priority to IL126460A priority patent/IL126460A/en
Priority to JP54284897A priority patent/JP3945822B2/en
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to CA2250723A priority patent/CA2250723C/en
Priority to AU32143/97A priority patent/AU719929B2/en
Priority to AT97927767T priority patent/ATE311463T1/en
Publication of WO1997044469A2 publication Critical patent/WO1997044469A2/en
Publication of WO1997044469A3 publication Critical patent/WO1997044469A3/en
Publication of WO1997044469A8 publication Critical patent/WO1997044469A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Multiple copy epitope immunoassays are produced by: (1) identifying nucleotide sequences that encode a plurality of different epitopes; (2) placing the nucleotide sequences into an expression cassette wherein at least two copies of a sequence coding for the same epitope, preferably from different strains of a pathogen, are placed in the cassette; (3) transforming a suitable host with the cassette in order to express the sequences encoding the epitopes; (4) purifying the expressed epitopes; and (5) coating the epitopes on a surface of a substrate. The purified epitopes are encompassed by the general structural formula (A)x-(B)y-(C)z which represents a linear amino acid sequence, B is an amino acid sequence of an epitope or cluster of epitopes and each B contains at least five and not more than 1,000 amino acids, y is an integer of 2 or more, A and C are each independently an amino acid sequence of an epitope or cluster of epitopes not adjacent to B in nature and x and z are each independently an integer of 0 or more wherein at least one of x and z is 1 or more. The epitopes of the invention are more soluble than and are therefore more easily purified than conventional epitopes. Further, the presence of repeating epitope sequences (repeating at least B in the same linear amino acid sequence from different strains of a pathogen) increases the sensitivity and specificity of the assay. Repeated epitope sequences in a single linear antigen also decreases masking problems and makes it possible to include a greater number of epitopes on a unit area of substrate thereby improving sensitivity in the detection of antibodies.
PCT/US1997/008950 1996-05-24 1997-05-23 Multiple epitope fusion protein WO1997044469A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AT97927767T ATE311463T1 (en) 1996-05-24 1997-05-23 FUSION PROTEIN WITH MULTIPLE EPITOPES
DE69734776T DE69734776T2 (en) 1996-05-24 1997-05-23 Fusion protein with multiple epitopes
EP97927767A EP0935662B1 (en) 1996-05-24 1997-05-23 Multiple epitope fusion protein
IL126460A IL126460A (en) 1996-05-24 1997-05-23 Multiple epitope fusion protein
JP54284897A JP3945822B2 (en) 1996-05-24 1997-05-23 Multiple epitope fusion protein
NZ333431A NZ333431A (en) 1996-05-24 1997-05-23 Multiple epitope fusion protein selected from HIV or HCV, method of immunoassay and assay device
CA2250723A CA2250723C (en) 1996-05-24 1997-05-23 Multiple epitope fusion protein
AU32143/97A AU719929B2 (en) 1996-05-24 1997-05-23 Multiple epitope fusion protein

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/653,226 US6514731B1 (en) 1996-05-24 1996-05-24 Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
US08/859,524 US6428792B1 (en) 1996-05-24 1997-05-20 Hepatitis C virus multiple copy epitope fusion antigens
US08/653,226 1997-05-20
US08/859,524 1997-05-20

Publications (3)

Publication Number Publication Date
WO1997044469A2 WO1997044469A2 (en) 1997-11-27
WO1997044469A3 true WO1997044469A3 (en) 1997-12-31
WO1997044469A8 WO1997044469A8 (en) 1999-07-22

Family

ID=27096474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/008950 WO1997044469A2 (en) 1996-05-24 1997-05-23 Multiple epitope fusion protein

Country Status (11)

Country Link
EP (1) EP0935662B1 (en)
JP (2) JP3945822B2 (en)
AT (1) ATE311463T1 (en)
AU (1) AU719929B2 (en)
CA (1) CA2250723C (en)
DE (1) DE69734776T2 (en)
DK (1) DK0935662T3 (en)
ES (1) ES2251028T3 (en)
IL (1) IL126460A (en)
NZ (1) NZ333431A (en)
WO (1) WO1997044469A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0870830A3 (en) * 1997-02-10 2004-02-25 Advanced Life Science Institute, Inc. Chimera hepatitis C virus antigen
JP4124961B2 (en) * 1997-09-22 2008-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド How to detect antibodies in a sample
ES2316171T3 (en) 1997-09-22 2009-04-01 Novartis Vaccines And Diagnostics, Inc. STAMPS TO STABILIZE HCV ANTIGENS.
AU746258B2 (en) * 1998-01-30 2002-04-18 General Hospital Corporation, The Genetic immunization with nonstructural proteins of hepatitis C virus
CN1305589A (en) 1998-04-17 2001-07-25 基因创新有限公司 Improved immunodiagnostic assays using reducing agents
WO1999058561A1 (en) * 1998-05-14 1999-11-18 Pasteur Merieux Serums & Vaccins Hepatitis c virus mimotopes
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
US6379903B1 (en) * 1999-10-08 2002-04-30 Sigma-Aldrich Co. Purification of recombinant proteins fused to multiple epitopes
US6562346B1 (en) 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
DE60035523T2 (en) * 1999-12-28 2008-03-20 Pharmexa Inc., San Diego OPTIMIZED MINIGENES AND THEREFORE ENCODED PEPTIDES
SI1354204T2 (en) 2000-06-15 2010-09-30 Novartis Vaccines & Diagnostic Hcv antigen/antibody combination assay
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
EP1829891B1 (en) 2000-06-15 2012-12-26 Novartis Vaccines and Diagnostics, Inc. Immunoassays for Anti-HCV Antibodies
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
CA2498228C (en) 2002-09-09 2011-03-22 Chiron Corporation Hcv assay
AU2003287188A1 (en) * 2002-10-25 2004-05-25 Chiron Corporation Activation of hcv-specific cells
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
ES2377978T3 (en) 2004-08-27 2012-04-03 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
EP2570423B1 (en) * 2005-06-17 2023-05-03 MSD Italia S.r.l. Hepatitis C virus nucleic acid vaccine
JP5215865B2 (en) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Norovirus and sapovirus antigens
US9598462B2 (en) * 2012-01-26 2017-03-21 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP2244695A1 (en) 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
CA2819416C (en) 2010-12-02 2019-04-30 Bionor Immuno As Peptide scaffold design
US9493514B2 (en) 2011-01-06 2016-11-15 Bionor Immuno As Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes
MX2014014683A (en) 2012-06-06 2015-02-24 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants.
IL282614B2 (en) 2015-02-06 2024-02-01 Cell Idx Inc Antigen-coupled immunoreagents
BR112017020539B8 (en) 2015-03-27 2024-01-09 Grifols Worldwide Operations Ltd Reagent for immunoassay comprising a polypeptide, methods of detecting antibodies and/or antigens to hepatitis c virus in a biological sample, of selecting biological samples from a supply of human biological samples, as well as isolated polypeptide and kit for immunodiagnostic testing
CN116515950A (en) * 2016-07-18 2023-08-01 赛尔伊迪克斯公司 Antigen-coupled hybridization reagents
KR101813586B1 (en) * 2016-12-29 2018-01-30 고려대학교 산학협력단 Protein nanoparticle linked with multiple disease specific marker epitope and ultra-sensitive method for detecting disease specific marker using it
WO2019020599A1 (en) 2017-07-27 2019-01-31 Roche Diagnostics Gmbh Multi-epitope fusion protein of an hcv antigen and uses thereof
KR101871985B1 (en) * 2017-08-14 2018-06-27 고려대학교 산학협력단 A Method and Kit for simultaneously detecting multiple diseases based on 3D protein nanoparticle probes
CN108794636B (en) * 2018-06-28 2020-05-22 中国人民解放军军事科学院军事医学研究院 Application of epitope polypeptide tandem mixture in immune protection against rickettsia rickettsii
KR102100813B1 (en) * 2018-11-08 2020-04-16 주식회사 보레다바이오텍 Fusion protein from hepatitis C virus and diagnosing kit comprising the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000365A2 (en) * 1991-06-24 1993-01-07 Chiron Corporation Hepatitis c virus (hcv) polypeptides
WO1993008280A1 (en) * 1991-10-16 1993-04-29 Immulogic Pharmaceutical Corporation Recombitope peptides
WO1994018234A1 (en) * 1993-02-10 1994-08-18 United Biomedical, Inc. Production of recombinant proteins containing multiple antigenic determinants linked by flexible hinge domains
WO1995003825A1 (en) * 1993-07-30 1995-02-09 Finn Olivera J Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
GB2294047A (en) * 1994-10-14 1996-04-17 Merck & Co Inc Synthetic peptides for use as epitopes specific for HIV

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000365A2 (en) * 1991-06-24 1993-01-07 Chiron Corporation Hepatitis c virus (hcv) polypeptides
WO1993008280A1 (en) * 1991-10-16 1993-04-29 Immulogic Pharmaceutical Corporation Recombitope peptides
WO1994018234A1 (en) * 1993-02-10 1994-08-18 United Biomedical, Inc. Production of recombinant proteins containing multiple antigenic determinants linked by flexible hinge domains
WO1995003825A1 (en) * 1993-07-30 1995-02-09 Finn Olivera J Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
GB2294047A (en) * 1994-10-14 1996-04-17 Merck & Co Inc Synthetic peptides for use as epitopes specific for HIV

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHATTERJEE S ET AL: "Fine specificity of immune responses to epitopic sequences in synthetic peptides containing B and T epitopes from the conserved Plasmodium falciparum blood-stage antigens.", VACCINE, 1995, 13 (15) P1474-81, ENGLAND, XP004057461 *
CHIEN D.Y. ET AL: "Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: Reevalutation of the role of HCV in liver disease", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 89, 1992, WASHINGTON US, pages 10011 - 10015, XP002044416 *
SMYTHE JA ET AL: "Production of linear polymers of HIV gp120-binding domains [letter]", PROTEIN ENG, FEB 1994, 7 (2) P145-7, ENGLAND, XP002044415 *
VAN DER PLOEG, J. R. ET AL: "Immunological properties of multiple repeats of a linear epitope of herpes simplex virus type 1 glycoprotein D", J. IMMUNOL. METHODS, 1989, 124, 211-17, XP002044417 *

Also Published As

Publication number Publication date
JP2007127671A (en) 2007-05-24
CA2250723A1 (en) 1997-11-27
DE69734776D1 (en) 2006-02-09
EP0935662A2 (en) 1999-08-18
DK0935662T3 (en) 2006-03-06
AU3214397A (en) 1997-12-09
IL126460A0 (en) 1999-08-17
JP3945822B2 (en) 2007-07-18
WO1997044469A2 (en) 1997-11-27
CA2250723C (en) 2012-07-17
WO1997044469A8 (en) 1999-07-22
EP0935662B1 (en) 2005-11-30
IL126460A (en) 2007-07-04
JP2001500723A (en) 2001-01-23
ATE311463T1 (en) 2005-12-15
AU719929B2 (en) 2000-05-18
ES2251028T3 (en) 2006-04-16
NZ333431A (en) 2000-05-26
DE69734776T2 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
AU3214397A (en) Multiple epitope fusion protein
ES2075196T3 (en) METHOD FOR USE AND SYNTHESIS OF PEPTIDES.
ATE206161T1 (en) CD 19 CODING DNA
HUP0002488A2 (en) Polyethylenimine-based biomolecule arrays
WO1995018826A3 (en) Purified primate ctla-8 antigens and related reagents
IL210454A0 (en) Novel cytokine zcytor17 ligand
FI961251A0 (en) Human metabotropic glutamate receptor subtypes (HMR4, HMR6, HMR7) and related DNA compounds
WO1999015666A3 (en) Macrophage derived chemokine (mdc), mdc analogs, mdc inhibitor sustances, and uses thereof
ATE399861T1 (en) SURFACE ANTIGENS FROM MAMMALS
WO1999009179A3 (en) Antigen constructs useful in the detection and differentiation of antibodies to hiv
Sledge et al. Antibody structure: amino terminal sequences of nurse shark light and heavy chains
DE3686452D1 (en) ACTIVATED BACILLUS THURINGIENSIS DELTA ENDOTOXIN, MADE BY A MANIPULATED HYBRID GENE.
EP0293079A3 (en) Chlamydia vaccine
EP0165658A3 (en) Methods and compositions for detection of legionnaires disease
EP0896058A4 (en) Novel semaphorin z and gene encoding the same
DK0773999T3 (en) OR-1, an orphan receptor belonging to the nuclear receptor family
WO2002033084A3 (en) Identification of the dombrock blood group glycoprotein as a polymorphic member of the adp-ribosyltransferase gene family
ATE133422T1 (en) PEPTIDES AND THEIR USE
DE3569161D1 (en) Process for assaying atl virus antibody and reagent therefore
WO1999055874A3 (en) Nucleic acids of the m antigen gene of histoplasma capsulatum, antigens, vaccines and antibodies, methods and kits for detecting histoplasmosis
SU676303A1 (en) Method of separating gaseous hydrocarbons
EP0949333A4 (en) Mutant measles virus antigens and genes encoding the same
TH33487B (en) Rabies vaccine that does not cause disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2250723

Country of ref document: CA

Ref country code: CA

Ref document number: 2250723

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997927767

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 542848

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 333431

Country of ref document: NZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 51/97 UNDER (30) REPLACE "NOT FURNISHED" BY "08/859524"

WWP Wipo information: published in national office

Ref document number: 1997927767

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997927767

Country of ref document: EP